Igc Pharma, Inc. · AMEX:IGC
Igc Pharma — Investor Presentation (July 2026)
25 slides from Igc Pharma's investor presentation, Jul 14, 2026
Slide 1: Advancing Alzheimer's Care. Improving Lives.
Advancing Alzheimer’s Care. Improving Lives. NYSE American: IGC
Slide 2: Safe Harbor: Forward-Looking Statements and Important Cautionary Information
SAFE HARBOR : Forward - Looking Statements and Important Cautionary Information: This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward - looking statements include statements regarding the timing, conduct and resul
Slide 3: Overview of IGC
OVERVIEW OF IGC IGC Pharma, Inc. · NYSE American: IGC
Slide 4: Investment Opportunity in Alzheimer's Disease: Illustrative Valuation Scenarios
INVESTMENT OPPORTUNITY IN ALZHEIMER’S DISEASE (AD) Illustrative Potential Valuation Scenarios → ~$30M ~$300 – $500M ~$2 – $4B 7/2026 Current market cap Near - term Potential inflection based on positive Phase 2 results Long - term Potential inflection if disease - modifying catalysts succeed Valuati
Slide 5: The Problem
THE PROBLEM One in three Americans over 85 has Alzheimer’sKM1
Slide 6: Agitation in Alzheimer's
AGITATION IN ALZHEIMER’S 76% of patients experience agitation or other neuropsychiatric symptoms 139M people projected to live with dementia by 2050 - Alzheimer’s is the leading cause Agitation is defined as physical or verbal aggression, restlessness, pacing, among others. Agitation drives earlier
Slide 7: Our Solution
OUR SOLUTION IGC Pharma is Developing a Major TherapyKM1
Slide 8: IGC-AD1 Therapeutic Targets
IGC - AD1 Therapeutic Targets Patent - protected Oral liquid — practical for elderly Alzheimer’s patients and caregivers Multiple neurobiological pathways targeted by IGC - AD1 Neuroinflammation CB1 receptor signaling Neurotransmitter regulation IGC - AD1 INVESTIGATIONAL IGC Pharma, Inc. · NYSE Amer
Slide 9: IGC-AD1
IGC - AD1 IGC Pharma, Inc. · NYSE American: IGC
Slide 10: Phase 1: NPS Measured by NPI-12
PHASE 1: NPS MEASURED BY NPI - 12 IGC - AD1 showed improvement in Neuropsychiatric Symptoms (NPS) in Phase 1 Trial Across qd , bid, & tid dosing, IGC - AD1 led to an overall improvement in NPS as measured by the NPI - 12 KEY DOMAINS SHOWING IMPROVEMENT: Agitation Anxiety Depression Caregiver Distres
Slide 11: Phase 2 CALMA Trial Status
PHASE 2 - CALMA TRIAL STATUS The multicenter CALMA trial of IGC - AD1 for agitation in Alzheimer’s dementia. 146 Target number of participants >80% of participants have completed dosing Previously reported interim analysis showed a reduction in agitation at 2 weeks NEAR - TERM CATALYSTS Completion o
Slide 12: Sites Conducting CALMA
UNITED STATES & CANADA ADDITIONAL SITES • Dent Neurosciences Research Center • BayCare Health System • ClinCloud • Global Medical Institutes Florida • Neurostudies • Tandem Intermediate • Tekton Research • Integrative Clinical Trials • Ichor Research • Lynn Health Science Institute • Senior Adults S
Slide 13: CALMA Phase 2 Progress Report: Blinded Pooled Data
CALMA PHASE 2 · PROGRESS REPORT BLINDED POOLED DATA Blinded pooled data include both IGC - AD1 and placebo participants and cannot establish treatment effect or efficacy; observed changes may not predict unblinded results 0 - 5 - 10 - 15 Baseline Week 2 Week 6 Visit LS Mean Change from Baseline (CMA
Slide 14: CALMA Interim Results: IGC-AD1 Compared to Brexpiprazole Data
CALMA INTERIM RESULTS (N=26): IGC - AD1 COMPARED TO BREXPIPRAZOLE DATA Brexpiprazole is the current standard of care to treat agitation in AD In interim analysis, IGC - AD1 showed numerically earlier and larger changes than those reported in selected published Brexpiprazole studies. IGC AD - 1: Pote
Slide 15: Interim Data: Potential for Reducing Sleep Disturbance
INTERIM DATA (n=26) - POTENTIAL FOR REDUCING SLEEP DISTURBANCE Clinical reduction in sleep & nighttime disturbance at week 2 sustained through End of Trial (EOT) - 1 - 2 - 3 - 4 - 5 1 2 EOT WEEK Placebo IGC - AD1 Active Placebo WEEK 2 Sleep Disturbance Reduced 71% (p=0.012) WEEK 6 (EOT) Sleep Distur
Slide 16: Approved Drugs (Competition)
APPROVED DRUGS (COMPETITION) AXS - 05 (Dextromethorphan and bupropion) A combination therapy approved in April 2026. IGC Pharma, Inc. · NYSE American: IGC Rexulti (Brexpiprazole) Atypical antipsychotic approved in May 2023 BLACK BOX WARNING
Slide 17: IGC Has Several Platforms with IP
IGC HAS SEVERAL PLATFORMS WITH IP Foreign Patents Granted US Patents Granted Pending Patent Applications Description Lead Drug Candidate - 2 1 ● Composition & Method for treating CNS Disorders IGC - AD1 1 1 9 ● Composition & Method for treating CNS Disorders IGC - AD1 - - 6 ● Naphthalene Monoimide D
Slide 18: Potential Catalysts
POTENTIAL CATALYSTS Laura Sanchez , Quality Control Manager & Dr. Jagadeesh Rao, Principal Scientist at IGC Pharma Headquarters in Potomac, MarylandKM1KM2
Slide 19: Market: Blockbuster Opportunity
MARKET: BLOCKBUSTER OPPORTUNITY North America & Europe market sizing for agitation in AD EST. ANNUAL REVENUE $3B 3% adoption $5B 5% adoption $10B 10% adoption ASSUMPTIONS 15M* Individuals with AD 11M Agitation in AD (76%) $750 Monthly price * Sources: Alzheimer’s Association, Alzheimer Europe, Harva
Slide 20: Valuation Inflection Examples
VALUATION INFLECTION EXAMPLES ~$30M $350 – $750M IGC today Potential Post Phase 2 valuation COMPANY PHASE 2 POST Positive PHASE 2 PEAK DIFFERENCE Annovis (ANVS) AD/PD $200M (2021) → $700M (2021) ~$500M Axsome (AXSM) AD $50M (2019) → $800M (2019) ~$750M Anavex AD/CNS $150M (2016) → $500M (2018) ~$350
Slide 21: Potential Valuation Inflection
POTENTIAL VALUATION INFLECTION Investors today are positioned before principal value - inflection events ~ $30m Current valuation July 10 2026 $350m – $750m 4 - 9 months 2026 - 2027 Positive phase 2 results $2B – $4B ~36 - 48 months 2029+ Positive phase 2 results in a disease - modifying therapy IGC
Slide 22: Executive Management & Board
EXECUTIVE MANAGEMENT & BOARD EXECUTIVE MANAGEMENT Ram Mukunda Biomedical Engineer CEO Claudia Grimaldi Psychologist, MBA, Vice President INDEPENDENT BOARD Richard Prins Chairman James Moran Former Congressman Terry Lierman Human Virology (IHV) CORPORATE ADVISORY BOARD Terry McAuliffe Former Governor
Slide 23: Team
TEAM IGC Pharma, Inc. · NYSE American: IGC Dr. Juan Manuel Orjuela, MD Neuropsychiatrist Dr. Diego Rodriguez, Ph.D. Medicinal Chemist Evelyn Gutiérrez, Eng. MPH Sr. Manager - CALMA Paola Ruiz, MS Sr. Manager AI Systems Maria Tangarife, MS Neuroscientist Margarita Venegas, MS Clinical Psychologist Dr
Slide 24: Board of Advisors
BOARD OF ADVISORS IGC Pharma, Inc. · NYSE American: IGC Prof. Elliot Hong, MD Professor Psychiatrist Prof. Chuanhai Cao, PhD Professor of Pharmaceutical Science s Prof. Jeffrey Cummings , MD, ScD, Chair of the ACTC Neuropsychiatric Symptoms Committee Prof. Pablo Arbelaez, PhD Professor Biomedical En
Slide 25: Contact
CONTACT Ram Mukunda ram@igcpharma.com Claudia Grimaldi cgrimaldi@igcpharma.com www.igcpharma.com THANK YOU Advancing Alzheimer’s Care . Improving Lives . NYSE American: IGC